Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Return on Invested Capital (ROIC)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| ROIC3 | ||||||
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2025 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The Return on Invested Capital (ROIC) exhibited significant fluctuations over the five-year period. Initial performance was strong, followed by a period of decline, and then a substantial recovery. A detailed examination of the components reveals the drivers behind these changes.
- Net Operating Profit After Taxes (NOPAT)
- NOPAT demonstrated a considerable decrease from 2021 to 2022, falling from US$6,897 million to US$3,687 million. A partial recovery was observed in 2023, with NOPAT reaching US$5,086 million. However, 2024 saw a significant loss, resulting in a negative NOPAT of US$796 million. A strong rebound occurred in 2025, with NOPAT increasing substantially to US$9,207 million.
- Invested Capital
- Invested capital generally decreased throughout the period. Beginning at US$47,782 million in 2021, it declined to US$45,565 million in 2022 and US$45,824 million in 2023. This downward trend continued, reaching US$44,333 million in 2024 and US$42,812 million in 2025. The rate of decline appeared to accelerate in the later years.
- Return on Invested Capital (ROIC)
- The ROIC mirrored the volatility in NOPAT. It began at a relatively high 14.43% in 2021, then decreased to 8.09% in 2022 and 11.10% in 2023. The negative NOPAT in 2024 resulted in a substantial negative ROIC of -1.80%. The significant increase in NOPAT in 2025 drove a dramatic recovery in ROIC, reaching 21.51%. This represents the highest ROIC value observed during the analyzed period.
The substantial decline in NOPAT in 2022 and the negative NOPAT in 2024 were primary drivers of the lower ROIC values in those years. While invested capital decreased consistently, the impact on ROIC was more pronounced due to the fluctuations in profitability. The strong recovery in NOPAT during 2025 had a disproportionately positive effect on ROIC, demonstrating the sensitivity of this metric to changes in operating performance.
Decomposition of ROIC
| ROIC | = | OPM1 | × | TO2 | × | 1 – CTR3 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | = | × | × | ||||
| Dec 31, 2024 | = | × | × | ||||
| Dec 31, 2023 | = | × | × | ||||
| Dec 31, 2022 | = | × | × | ||||
| Dec 31, 2021 | = | × | × |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The period under review demonstrates significant fluctuations in the components of return on invested capital. Overall, ROIC experienced volatility, beginning at 14.43%, declining to 8.09%, increasing to 11.10%, then sharply decreasing to -1.80% before recovering substantially to 21.51%.
- Operating Profit Margin (OPM)
- The operating profit margin exhibited considerable variation. It decreased from 34.43% in 2021 to 24.71% in 2022, then recovered to 27.67% in 2023. A substantial decline to 4.92% occurred in 2024, followed by a strong rebound to 36.25% in 2025. This suggests potential shifts in cost management or pricing strategies impacting profitability.
- Turnover of Capital (TO)
- Turnover of capital showed a gradual increasing trend. Starting at 0.57 in 2021, it rose to 0.59 in both 2022 and 2023, then further increased to 0.65 in 2024 and 0.68 in 2025. This indicates improving efficiency in utilizing capital to generate revenue.
- Effective Cash Tax Rate Adjustment (1 – CTR)
- The adjustment for the effective cash tax rate was highly volatile. It began at 74.16% in 2021, decreased to 55.30% in 2022, and increased to 68.25% in 2023. A significant negative value of -56.51% was recorded in 2024, likely indicating tax benefits or loss carryforwards, before rising sharply to 87.85% in 2025. This factor had a substantial impact on ROIC, particularly in 2024.
The interplay between these three components – operating profit margin, turnover of capital, and the effective cash tax rate adjustment – explains the observed ROIC fluctuations. The negative ROIC in 2024 was primarily driven by the exceptionally low operating profit margin, despite a positive trend in capital turnover, and the negative tax adjustment. The substantial recovery in ROIC in 2025 is attributable to the significant improvement in operating profit margin and a positive tax adjustment, partially offset by a smaller increase in capital turnover.
Operating Profit Margin (OPM)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Add: Cash operating taxes2 | ||||||
| Net operating profit before taxes (NOPBT) | ||||||
| Product sales | ||||||
| Profitability Ratio | ||||||
| OPM3 | ||||||
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2025 Calculation
OPM = 100 × NOPBT ÷ Product sales
= 100 × ÷ =
4 Click competitor name to see calculations.
The operating profit margin exhibited significant fluctuations over the five-year period. Initial profitability was strong, followed by a substantial decline, a partial recovery, and then a dramatic increase.
- Operating Profit Margin (OPM) - Overall Trend
- The OPM began at 34.43% in 2021, representing a high level of profitability. A marked decrease was observed in 2022, falling to 24.71%. A modest recovery occurred in 2023, with the OPM reaching 27.67%. However, 2024 witnessed a precipitous drop to 4.92%, indicating a significant erosion of profitability. The final year, 2025, showed a substantial rebound, with the OPM increasing to 36.25%, surpassing the initial value in 2021.
- Relationship to Net Operating Profit Before Taxes (NOPBT)
- The fluctuations in OPM correlate with changes in NOPBT. The decline in OPM in 2022 and 2024 aligns with lower NOPBT values of US$6,668 million and US$1,409 million, respectively. Conversely, the increase in OPM in 2023 and 2025 corresponds with increases in NOPBT to US$7,453 million and US$10,480 million, respectively. This suggests a strong link between overall profitability and the operating margin.
- Relationship to Product Sales
- Product sales remained relatively stable between 2021 and 2023, fluctuating within a narrow range of approximately US$26.9 billion to US$27.1 billion. The significant change in OPM was not directly driven by substantial shifts in product sales during these years. However, in 2024, product sales increased to US$28.61 billion, yet the OPM decreased dramatically, indicating that increased sales volume did not translate into increased profitability. The subsequent increase in OPM in 2025, alongside a further increase in product sales to US$28.915 billion, suggests improved cost management or pricing power in that year.
The volatility in OPM highlights potential underlying factors affecting profitability, such as changes in cost of goods sold, research and development expenses, or pricing strategies. The substantial recovery in 2025 warrants further investigation to understand the drivers behind the improved margin.
Turnover of Capital (TO)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Product sales | ||||||
| Invested capital1 | ||||||
| Efficiency Ratio | ||||||
| TO2 | ||||||
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Invested capital. See details »
2 2025 Calculation
TO = Product sales ÷ Invested capital
= ÷ =
3 Click competitor name to see calculations.
The analysis reveals a consistent upward trend in the turnover of capital over the five-year period. While product sales demonstrate relative stability with a slight increase overall, the more significant driver of the turnover improvement appears to be a decrease in invested capital.
- Product Sales
- Product sales remained relatively consistent between 2021 and 2023, fluctuating around US$27 billion. A moderate increase is observed in 2024 and 2025, reaching US$28.61 billion and US$28.915 billion respectively. This suggests a gradual growth in sales generation.
- Invested Capital
- Invested capital experienced a decline throughout the period. Starting at US$47.782 billion in 2021, it decreased to US$42.812 billion by 2025. This consistent reduction in capital employed represents a potential increase in capital efficiency.
- Turnover of Capital (TO)
- The turnover of capital ratio increased steadily from 0.57 in 2021 to 0.68 in 2025. This indicates that the company is generating more sales revenue for each dollar of invested capital. The most substantial increase occurred between 2023 and 2024, moving from 0.59 to 0.65, and continued into 2025. This improvement suggests enhanced operational efficiency or a more effective utilization of assets.
The combined effect of stable sales and decreasing invested capital has resulted in a positive trend in the turnover of capital. This suggests the company is becoming more efficient in generating revenue from its capital base.
Effective Cash Tax Rate (CTR)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Add: Cash operating taxes2 | ||||||
| Net operating profit before taxes (NOPBT) | ||||||
| Tax Rate | ||||||
| CTR3 | ||||||
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2025 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =
4 Click competitor name to see calculations.
The effective cash tax rate exhibited considerable fluctuation over the five-year period. Cash operating taxes generally decreased from 2021 to 2025, while net operating profit before taxes demonstrated a more volatile pattern. This interplay resulted in significant shifts in the effective cash tax rate.
- Effective Cash Tax Rate (CTR) - Trend Analysis
- In 2021, the effective cash tax rate was 25.84%. This increased substantially to 44.70% in 2022, indicating a higher proportion of pre-tax profits being paid in cash taxes. The rate then decreased to 31.75% in 2023. A dramatic spike occurred in 2024, with the effective cash tax rate reaching 156.51%. This suggests a disproportionately large cash tax expense relative to pre-tax income during that year. Finally, the rate declined significantly to 12.15% in 2025, representing the lowest value within the observed period.
The substantial increase in the effective cash tax rate in 2024 warrants further investigation. While net operating profit before taxes decreased significantly in 2024, the cash operating taxes remained relatively stable compared to the prior year. This discrepancy likely drove the exceptionally high rate. The subsequent decrease in 2025, coinciding with a substantial increase in net operating profit before taxes and a decrease in cash operating taxes, suggests a return to a more typical tax burden.
- Relationship between NOPBT and Cash Taxes
- The relationship between net operating profit before taxes and cash operating taxes is not consistently proportional. In 2022, the increase in the effective cash tax rate coincided with a decrease in net operating profit before taxes. Conversely, in 2025, the decrease in the effective cash tax rate occurred alongside an increase in net operating profit before taxes. This suggests factors beyond simple profitability are influencing the cash tax expense.
The volatility in the effective cash tax rate highlights the importance of understanding the underlying drivers of cash tax payments. Fluctuations could be attributable to changes in tax legislation, deferred tax asset realization, or specific tax planning strategies employed by the company.